Schizophrenia Flashcards
who was Emil Kraepelin (1898)
- at this time SZ patients were first systematically described as separate psychiatric category of patients
- first to describe symptoms of SZ patients
- Described symptoms of patients as ‘dementia praecox’:
- dementia = global disruption of perceptual and cognitive processes
- praecox = early adulthood onset
- Main symptoms: impairments in attention, memory and goal-directed behaviour
- Described condition as progressive, no return to premorbid functioning
who was Eugen Bleuler (1911)
- Reformulated dementia praecox
- Coined the term schizophrenia:
- schizo = split
- phrene = mind
- Characterised fragmented thinking
- First to distinguish between positive and negative symptoms
what is Schizophrenia?
- as defined in the Diagnostic and Statistical Manual of Mental Disorders (or DSM), schizophrenia is characterized by a combination of positive and negative symptoms and these can be demonstrated to variable degrees
- one patient could show predominantly positive symptoms, but not as many negative symptoms, while another patient may show mainly negative symptoms.
- has positive and negative symptoms as well as cognitive deficits (70-80% of patients have cognitive deficits)
what are positive (type 1) symptoms?
delusions:
- false belief despite evidence to contrary, distorting reality (e.g. patient beliefs someone is plotting against them)
- thought insertion
- thought withdrawal
- thought broadcasting
- not being in control of own actions
Hallucinations:
- perceptual experience seems real in absence of physical proof; most common: auditory, visual, olfactory (e.g seeing an animal or person that isn’t real)
Disorganised behaviour
- can affect speech, difficulties with routine tasks, inappropriate behaviour
what are negative (type II) symptoms
diminished emotional expression
- affect: blunted affect, mood or emotional state, limited range of emotions
- alogia: poverty of speech, lack of conversation
Avolition
- apathy (lack of motivation)
- social withdrawal
- Anhedonia: inability to feel pleasure
what are cognitive deficits?
- substantial impairment in overall cognitive performance (occurs in most SZ patients)
- can be variable across patients
most common deficits in: - executive functions/cognitive control (incl. verbal frequency and problem solving
- attention (incl. vigilance)
- processing speed
- memory (working memory, episodic memory)
- social cognition
Presence of cognitive deficits associated with poor daily functioning and quality of life
tetsing for cognitive deficits
- Impairments in cognitive functions already detectable in childhood/adolescence neurodevelopmental disorder
- Objective assessment of cognitive impairments and subjectively perceived impairments only weakly correlated
- anosognosia for cognitive deficits (in particular, in individuals with more severe deficits)
Schizophrenia as a neurodevelopmental disorder
- SZ is a neurodevelopmental disorder
- typically develops during late adolescence
- cognitive impairments can often be detected much earlier, i.e. in childhood or early adolescence
- Brain abnormalities slowly emerge during adolescence, therefore it is described as neuro developmental condition.
- Combination of genetics and environment (~80% heritable)
- Prevalence of SZ: 1%
what are the genetic risk factors of developing SZ?
- Children or siblings of affected individuals 10 x more likely to develop SZ
- Polygenic disorder: at least 108 genes implicated
- Genetics only explain small percentage of cognitive variance
what are the environmental risk factors of developing SZ?
- adverse events prenatally or perinatally (adverse events before or during birth) (e.g. poor maternal nutrition, infection, obstetric complications)
- Perinatal hippocampal injuries in rats ➟ development of abnormal dopamine organization in prefrontal cortex
- Contact with certain viruses in early childhood might increase risk
- Growing up in urban environment
- Air pollution
- Drugs: some individuals develop SZ after taking certain drugs, e.g. cannabis
what are the 4 neurotransmitters involved in SZ?
- Dopamine = linked with positive symptoms and attention, WM, cognitive control
- Acetylcholine = linked to attention and memory
- Glutamate (Glu) = main excitatory neurotransmitter
- GABA = main inhibitory neurotransmitter
what is the dopamine hypothesis?
dopamine hypothesis:
- Important role of mesocortical dopaminergic pathway (from tegmentum)
- dopaminergic agonist, i.e. drugs that increase dopamine levels, like cocaine, amphetamine or L-Dopa, can induce psychotic symptoms, which resemble positive symptoms in individuals with schizophrenia
- plausible to assume a crucial role of the DA system in schizophrenia, with high levels of dopamine causing positive symptoms
- Disturbances in this transmitter system could explain various cognitive impairments seen in individuals with schizophrenia
- Typical antipsychotic medication reduces DA levels in the brain
- these reduce positive symptoms
- but not very effective at attenuating the negative symptoms; on the contrary, they sometimes even worsen the negative symptom
dopamine hypothesis: dissociation between cortical and striatal DA
- suggested that there is a dissociation between cortical and striatal DA.
- There might be too little DA in cortical areas, i.e. a hypo-dopaminergic state
- there might be too much DA in the striatum, i.e. a hyper-dopaminergic state in the striatum
- DA levels fluctuate in individuals with SZ over time, cognitive symptoms much more stable -> close link is unlikely
Overall, the DA hypothesis cannot be the whole story. Usually, modulations in one transmitter system can also affect other neurotransmitter systems
Glutamate (Glu)
- glutamate plays a central role in schizophrenia, and that the dysregulation of the dopaminergic system is only secondary to impaired glutamatergic functions
- Glu is the main excitatory neurotransmitter in the brain, and Glu levels can modulate DA release in the Ventral Tegmental Area, so DA and Glu systems are not working independently, but they interact.
- Postmortem brains of schizophrenia patients: loss of Glu neurons in ACC (and other brain areas; Squires et al., 1993)
Moghaddam & Javitt (2012): 2 phases of Glu modulations in SZ patients
- NMDA-mediated interneuron dysfunction ➜ loss of inhibitory control, increased Glu levels
- Glu-induced excitotoxicity ➜ loss of Glu connections; decreased Glu levels
what is Magnetic Resonance Spectroscopy (MRS)
- MRS has been used to measure neurometabolites in vivo. The advantage of MRS, compared to PET studies, for instance, is that neurotransmitter levels can be quantified without using radioactive tracers as MRS can be done by using a standard MRI scanner.
- The methods for MRS are still evolving and scanning sequences are being optimised for certain neurotransmitters so the results of these MRS studies have been quite mixed in the past, but they will get more precise over time.
Meta analysis of MRS studies in psychosis patients, Sydnor & Roalf (2020)
- meta-analysis to find a common pattern in neurometabolite changes in psychosis patients compared to healthy controls
- found no significant different between patients and healthy controls in that study
- results are mixed with some studies finding decreases in Glu and others finding increases. However, in a meta-analysis you can combine all the available data.
- overall, patients show reduced glutamate levels, which would be expected in chronic schizophrenia patients
- A similar finding has been reported for glutathione, a major antioxidant in the brain, that has a close relationship to glutamate and is also reduced in individuals with schizophrenia.
Neurotransmitters and the multiple systems affected
- Newer, atypical antipsychotics target a variety of neurotransmitters, e.g. DA in addition to serotonin and adrenaline
- Neurotransmitter systems seem to be affected to different degrees in patients; might explain the variability between patients and ehy available drugs are not effective to same extent in all patients
Differences in brain anatomy in patients with SZ and without
Post-mortem studies have shown that brains of schizophrenia patients weigh less than the average weight of neurologically healthy people. This weight loss might be explained by the following observations:
- SZ patients show enlarged ventricles, which suggests a loss of / or fewer long range white matter fiber connections. Examples for enlarged ventricles can be seen on the pictures on the right side
- Individuals with schizophrenia have a reduced number of neurons in prefrontal cortex areas and thinner parahippocampal gyri, indicating fewer cells in these structures as well.
- Neurons in prefrontal and hippocampal areas show a different structure in patients compared to controls
Meta-analysis investigated grey matter (GM) loss in individuals with SZ Liloia et al. (2021, NBR)
- In chronic SZ GM is reduced in
- the medial frontal and anterior cingulate cortex
- the insular cortex is affected bilaterally
- Left thalamus and caudate
- Amygdala bilaterally
- These structures play a role in decision-making, for example. The amygdala has been associated with processing of emotions, but recently also with the integration of social cues to guide decision-making and other cognitive processes.
why can it be hard to develop treatments for cognitive symptoms of schizophrenia?
- cognitive impairments in schizophrenia patients comprise a large range of different cognitive processes: executive functions, working memory, language, episodic memory, processing speed, attention, inhibition and sensory processing
- This large range of cognitive symptoms makes it difficult to understand the underlying mechanisms and therefore it’s also difficult to develop effective interventions.
Cognitive symptoms associated with schizophrenia, Barch & Ceaser (2012)
- Barch & Ceaser (2012) proposed the hypothesis Common mechanism across cognitive domains ’context processing’, ‘WM’ and ‘episodic memory
- They suggest that individuals with SZ show an impairment in representing goal information in WM to guide behaviour this is called proactive control
- Proactive control has been associated with a representation of information, and therefore an activation, in the dorsolateral prefrontal cortex (or DLPFC)
Dual mechanisms of control (Braver et al., 2009)
- For all goal-directed behaviour, we first need to have a goal. Goals are intended outcomes of actions or mental operations.
- Goals need to be actively represented in WM before a task starts or a decision is made so that they can trigger appropriate actions or mental operations. This part of the model is what Barch & Ceaser refer to as ‘proactive control’.
- Proactive control also allows for biasing our attention, perception or motor systems in a goal-driven manner
- The goal representation then elicits an action and we can observe an outcome
- When we have completed an action, we also need the goal representation for the subsequent monitoring process. This refers to the evaluation if what we have achieved with our action, matches our intended goal. These monitoring processes have been associated with activity in medial frontal cortex areas, including the ACC.
- In case we have missed our goal, we might adjust various processes to be able to achieve the goal the next time we try
Barch & Ceaser have suggested that it’s the proactive control aspect that is impaired in individuals with schizophrenia. These individuals would need to rely more on reactive control when completing tasks.
Association between proactive control deficits in schizophrenia and impairments in DLPFC activity, Barch & Ceaser (2012)
- Meta-analysis Minzenberg et al., (2009)
- fMRI studies showed reduced DLPFC activity in schizophrenia patients in tasks that require proactive control